September 21, 2026
| Trial | DESTINY Gastric05 |
|---|---|
| Cancer Type | Gastrointestinal and Stomach Cancer |
| Hospital(s) | Altnagelvin Hospital |
| Information | A Multicenter, Randomized, Open-label, Phase 3 Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab as First-line Treatment in Participants with Unresectable, Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction (GEJ) Cancer |
| Trial Open | Yes |